As Ranbaxy Founders Exit, Daiichi Sankyo Assumes Complete Control; New Management Expects To Resolve U.S. FDA Issue
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Less than one year after acquiring a 64 percent equity stake in India's Ranbaxy for $4.6 billion, Japanese drug maker Daiichi Sankyo has taken complete control of the company's management after reaching an "amicable" agreement on the exit of Malvinder Singh, the grandson of Ranbaxy's founder, and two other directors: Sunil Godhwani and Balinder Dhillon
You may also be interested in...
Final Assault: Daiichi Sankyo Threatens Legal Action Against Former Ranbaxy Shareholders For Concealing Information
Breaking its silence after four years, Daiichi Sankyo hinted for the first time that it would pursue legal remedies against former shareholders of Ranbaxy, which the Japanese company bought in 2008 to expand into emerging markets and the generics drug space.
Is Ranbaxy Inching Closer To Resolution Of Its GMP Disputes With U.S. FDA?
MUMBAI - After more than two years of serious deliberations, Ranbaxy seems to be finally moving forward to resolve charges of significant manufacturing lapses leveled by U.S. FDA at two of its India-based sites
Is Ranbaxy Inching Closer To Resolution Of Its GMP Disputes With U.S. FDA?
MUMBAI - After more than two years of serious deliberations, Ranbaxy seems to be finally moving forward to resolve charges of significant manufacturing lapses leveled by U.S. FDA at two of its India-based sites